Is Moderna Stock a Buy After Its Melanoma Breakthrough?

Moderna's successful Phase 3 melanoma study provides a potential non-COVID catalyst by validating its personalized mRNA cancer-treatment platform. The result strengthens the investment case for oncology, although the stock's substantial rerating raises uncertainty over whether the opportunity can develop into a durable growth driver.